# US 2021/0231649 A1 · Magnetic nanosphere coated with modified cardiolipin, and manufacturing method thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0231649 A1
- Document ID: US20210231649A1
- Status: Published application
- Kind: A1
- Application number: 16/313,907
- Filed: 2016-06-30
- Published: 2021-07-29
- Earliest claimed: 2016-06-30
- Assignees: Shenzhen Yhlo Biotech Co., Ltd.
- Applicants: Shenzhen Yhlo Biotech Co., Ltd.
- Inventors: Fuzhen XIA; Dingbiao ZOU; Gang WANG; Xiaoqin YE; Chungen QIAN
- Web page: https://patentgrep.com/patent/US20210231649A1

## CPC

- G01N 33/5434: {using magnetic particle immunoreagent carriers which constitute new materials per se}
- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- G01N 33/531: Production of immunochemical test materials
- G01N 33/54333: {Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction}
- H01F 1/0054: {Coated nanoparticles, e.g. nanoparticles coated with organic surfactant}
- B82Y 15/00: Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
- B82Y 25/00: Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
- B82Y 40/00: Manufacture or treatment of nanostructures
- G01N 2405/04: Phospholipids, i.e. phosphoglycerides
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- H01F: MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

Provided in the present invention are a magnetic nanosphere coated with modified cardiolipin, and manufacturing method thereof. The magnetic nanosphere coated with modified cardiolipin comprises a modified cardiolipin, a biotin derivative, and a streptavidin magnetic bead. The modified cardiolipin is coupled to the biotin derivative via an —NH—CO structure. The streptavidin magnetic bead is a magnetic nanosphere coupled to streptavidin, and the biotin derivative is coupled to the streptavidin.

## Claims

### Claim 1

A modified cardiolipin-coated magnetic nanobead comprises: a modified cardiolipin, a biotin derivative and a streptavidin magnetic bead;
the modified cardiolipin is obtained by oxidizing and aminating a hydrophobic fatty acid side chain of cardiolipin, and the modified cardiolipin contains −NH2;
The biotin derivative has a structural formula of
wherein —R— is a saturated alkyl chain having 4 to 20 carbon atoms or a polyethylene glycol chain having 2 to 10 carbon atoms, —NH2 in the modified cardiolipin and -COOH in the biotin derivative form a —NH—CO—structure to link the modified cardiolipin and the biotin derivative together;
the streptavidin magnetic bead is a streptavidin-binding magnetic nanobead, and the biotin derivative is linked to streptavidin.

### Claim 2 (depends on 1)

The modified cardiolipin-coated magnetic nanobead according to claim 1, wherein the —R— is a saturated alkyl chain containing 4 to 10 carbon atoms.

### Claim 3 (depends on 1)

The modified cardiolipin-coated magnetic nanobead according to claim 1, wherein the modified cardiolipin contains one —NH2.

### Claim 4 (depends on 3)

The modified cardiolipin-coated magnetic nanobeads according to claim 3, wherein the modified cardiolipin has a structural formula as follows:

### Claim 5 (depends on 1)

A method for preparing the modified cardiolipin-coated magnetic nanobead according to claim 1, comprises:
reacting cardiolipin with a peroxide sufficiently in the presence of a first solvent to obtain an intermediate product;
adding excess ammonia water to the intermediate product and reacting sufficiently to obtain the modified cardiolipin, wherein a hydrophobic fatty acid side chain of the modified cardiolipin is oxidized, and the modified cardiolipin contains an amino group;
reacting the modified cardiolipin with a biotin derivative sufficiently in the presence of a second solvent to obtain a a modified biotin derivative-binding cardiolipin, wherein the biotin derivative has a structural formula of
wherein —R— is a carbon chain having 4 to 20 carbon atoms or a polyethylene glycol chain having 2 to 10 carbon atoms, —NH2 in the modified cardiolipin and COOH in the biotin derivative form a —NH—CO—structure to link the modified cardiolipin and the biotin derivative together, thereby producing a modified biotin derivative-binding cardiolipin; and
mixing and sufficiently reacting the modified biotin derivative-binding cardiolipin with a streptavidin magnetic bead to obtain the modified cardiolipin-coated magnetic nanobead, wherein the streptavidin magnetic bead is a streptavidin-binding magnetic nanobeads, and the biotin derivative is linked to streptavidin.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the peroxide is peroxybenzoic acid, m-chloroperoxybenzoic acid, peroxyacetic acid, or peroxypropionic acid, a molar ratio of cardiolipin to the peroxide ranges from 1:1 to 1:8, and the first solvent is dichloromethane, trichloromethane, chloroform, benzene, or toluene, in the operation for reacting cardiolipin with the peroxide sufficiently in the presence of the first solvent.

### Claim 7 (depends on 5)

The method according to claim 5, wherein ammonia water has a mass concentration ranging from 10% to 30% in the operation for adding excess ammonia water to the intermediate product and reacting sufficiently.

### Claim 8 (depends on 5)

The method according to claim 5, wherein the second solvent is DMSO, DMF, tetrahydrofuran, or phosphate-buffered saline having a pH of 6.5 to 8.5 in the operation for reacting the modified cardiolipin with the N-hydroxysuccinimide-activated biotin derivative sufficiently in the presence of the second solvent.

### Claim 9 (depends on 5)

The method according to claim 5, wherein a molar ratio of the modified cardiolipin to the N-hydroxysuccinimide-activated biotin derivative ranges from 1:1.5 to 1:20 in the operation for reacting the modified cardiolipin with the N-hydroxysuccinimide-activated biotin derivative sufficiently in the presence of the second solvent.

### Claim 10 (depends on 5)

The method according to claim 5, wherein the modified biotin derivative-binding cardiolipin has a concentration of 0.1 mg/mL to 1 mg/mL, and the streptavidin magnetic bead has a concentration of 5 mg/mL to 15 mg/mL in the operation for mixing and sufficiently reacting the modified biotin derivative-binding cardiolipin with the streptavidin magnetic bead.
